Grants8 logo Grants8
Login Create account

Grant Details

Grant Analysis

Purpose & Target

The core objective of this grant is to facilitate sustained collaboration among national and regional cancer funders across Europe. It aims to support the EU Cancer Mission's objectives through coordinated translational cancer research. - Target recipient type: National and regional public funding bodies, research organizations (e.g., universities, research institutes), foundations, and charities involved in cancer research funding. - Target recipient size: No specific size defined, but entities capable of managing large-scale coordination and pooling significant financial resources. - SECTOR-SPECIFIC: Healthcare, Research funding, Public Administration (for funding bodies). - Geographic scope: European Union Member States and Horizon Europe Associated Countries. - Key filtering criteria: Focus on translational cancer research; ability to coordinate and launch joint transnational calls; commitment to the EU Cancer Mission. - Grant frequency and program context: This is part of the Horizon Europe Work Programme 2025, specifically under the Mission on Cancer. Opportunities within this mission are likely to recur.

Financial Structure

  • Total budget for this specific topic: EUR 5,000,000.
  • The grant will take the form of a 'lump sum contribution'.
  • Minimum and maximum funding per grant is EUR 5,000,000.
  • Eligible costs are determined based on an approximation of underlying actual costs, covering:
    • Personnel costs (employees, seconded persons, SME owners).
    • Subcontracting costs.
    • Purchase costs (travel, equipment, other goods and services).
    • Other cost categories (e.g., financial support to third parties if applicable to the action type, internally invoiced goods/services).
  • Indirect costs are calculated at a flat rate of 25% of qualifying direct costs and are included in the lump sum.
  • The lump sum includes the applicable reimbursement rates; for Coordination and Support Actions (CSA), the typical funding rate is 100% of eligible costs.
  • Payments are based on the proper implementation of 'work packages' (as defined in Annex 1 of the grant agreement), not on actual incurred costs.
  • Between 5% and 8% of the total lump sum is retained as contribution to the Mutual Insurance Mechanism.
  • The co-financing principle will be applied, meaning the total estimated costs of the action are expected to be greater than the estimated Union contributions, or the Union contribution partially covers the total costs.
  • The EU contribution cannot be used to co-fund the grants issued by the national/regional funders to third parties (i.e., the research projects funded through the joint calls that are an outcome of this action).

Eligibility Requirements

Organization Type
  • Open to legal entities from EU Member States and Horizon Europe Associated Countries.
  • Expected types include national and regional public funding bodies, research organizations (e.g., universities, research institutes), foundations, and charities involved in cancer research funding.
  • Must be able to 'pool necessary financial resources' for joint transnational calls.
Consortium Requirements
  • Application must be submitted by a consortium.
  • Consortium should include 'national and regional cancer funders across Europe (i.e., representing Northern, Southern, Central, Eastern and Western Europe)'.
Financial and Operational Capacity
  • Applicants must demonstrate sufficient financial and operational capacity as described in Annex C of the Horizon Europe Work Programme General Annexes.
Exclusions
  • Organizations under exclusion criteria described in Annex C of the Work Programme General Annexes.
  • EU contribution will not be used to co-fund grants to third parties directly. The action is for coordination and support, not direct research funding to third parties.

Application Process

Application Deadline
  • Submission deadline: 2025-09-16.
Submission Process
  • Single-stage submission model.
  • Application must be submitted via the Funding & Tenders Portal.
  • Applicants must use the standard application form (HE CSA) and provide a detailed budget table (HE LS).
Required Documentation
  • Proposal (Part B of the Application Form), adhering to page limits and layout described in Annex A and E of the Horizon Europe Work Programme General Annexes.
  • Detailed budget table.
Evaluation Process
  • Proposals will be evaluated by external independent experts.
  • Financial aspects of the lump sum budget will be checked by experts with financial expertise against benchmarks.
  • An indicative timeline for evaluation and grant agreement is described in Annex F of the Work Programme General Annexes (specific dates not provided in source).
Support Offered
  • Support available through the Horizon Europe Programme Guide, Online Manual, Funding & Tenders Portal FAQ, Research Enquiry Service, National Contact Points (NCPs), Enterprise Europe Network, and IT Helpdesk.
Post-Award Requirements
  • Reporting will primarily focus on the technical implementation and achievement of work package conditions.
  • Checks and audits will focus on technical implementation and compliance with lump sum conditions, ethics, research integrity, dissemination and exploitation of results, intellectual property management, and gender equality.

Evaluation Criteria

Excellence
  • Quality of objectives, and the extent to which they are ambitious, clearly defined, and address the specific topic.
  • Soundness of the proposed methodology, including interdisciplinary approaches, use of open science practices, and FAIR data principles.
  • Quality of the proposed coordination and networking activities for funding agencies.
Impact
  • Contribution to the EU Cancer Mission objectives (improving understanding of cancer, enhancing prevention, optimising diagnosis/treatment, improving quality of life, accelerating digital transformation).
  • Potential for delivering at least four joint transnational calls for proposals.
  • Potential for streamlining funding practices and exploring novel funding schemes.
  • Demonstration of leverage effect on European and national research and competitiveness using key indicators.
  • Contribution to social, economic, and environmental impacts related to cancer.
Quality and Efficiency of the Implementation
  • Quality and effectiveness of the work plan, including the appropriateness of the allocation of tasks and resources.
  • Complementarity of the participants within the consortium, including their individual expertise and experience in national/regional cancer funding and translational research.
  • Appropriateness of the management structures and procedures, including risk management.
  • Detailed cost estimation and justification for the proposed lump sum budget, assessed for its alignment with activities and expected outputs.
Scoring and Thresholds
  • Each criterion (Excellence, Impact, Implementation) has a threshold of 4 out of 5.
  • The cumulative threshold for all criteria is 12 out of 15.

Compliance & Special Requirements

Regulatory Compliance
  • Compliance with EU Financial Regulation 2024/2509.
  • Adherence to Horizon Europe rules and General Annexes regarding admissibility, eligibility, financial/operational capacity, evaluation, and legal/financial setup of grants.
Data and Ethics
  • Datasets produced by collaborative grants to third parties should be made 'FAIR' (Findable, Accessible, Interoperable, Reusable) whenever possible.
  • Tools and models should follow 'open science' principles.
  • Proposals must consider ethical aspects, research integrity, and gender equality.
Intellectual Property
  • Management of intellectual property is a focus during post-award checks, aligning with Horizon Europe rules for dissemination and exploitation.
Risk Management
  • Risk management expectations are integrated into the 'Quality and efficiency of the implementation' evaluation criterion.
Unique Aspects
  • The grant utilizes a 'lump sum' funding model, which simplifies financial reporting by focusing on work package completion and outputs rather than detailed cost documentation. This shifts emphasis towards 'scientific/technical performance and output'.
  • Classified as a 'Coordination and Support Action' (CSA), meaning its primary goal is networking, coordination, and supporting other activities, not direct funding of individual research projects.
  • Strong emphasis on 'transnational cooperation' and 'pooling financial resources' among funding bodies to amplify impact.
Cross-Cutting Themes
  • Promotes 'equitable access' in all areas of the cancer mission (prevention, diagnosis, treatment, quality of life).
  • Aligns with transversal priorities of the Cancer Mission: 'innovation', 'childhood cancer', 'personalised medicine', and 'citizen engagement'.
  • Encourages the integration of 'AI, machine learning and deep learning' approaches where relevant.
  • Seeks synergies with other EU programmes (e.g., EU4HEALTH, EURATOM, Digital Europe, Erasmus+, European Green Deal).

Grant Details

cancer oncology translational research cancer funding research collaboration national funders regional funders charities foundations healthcare european research area innovation health mission eu funding horizon europe coordination action support action public health medical research health policy data sharing fair data open science ai machine learning deep learning digital health european union
Sustained collaboration of national and regional cancer funders to support the Cancer Mission through translational research
HORIZON-MISS-2025-02-CANCER-01
Horizon Europe
OTHER UNIVERSITY PUBLIC NGO
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE AL AM BA GE IS IL MD ME MK NO RS TR UA UK
HEALTHCARE OTHER
DEVELOPMENT MATURE
OTHER
SDG3 SDG9 SDG17
FUNDING CAPACITY_BUILDING NETWORKING RESEARCH_DEVELOPMENT OPERATIONAL_SUPPORT
5000000.00
5000000.00
5000000.00
EUR
100.00
Sept. 16, 2025, midnight
None